Total Payments
$247,508
2022 Payments
$1,250
Companies
20
Transactions
438
Medicare Patients
1,132
Medicare Billing
$79,910
Payment Breakdown by Category
Other$106,697 (43.1%)
Consulting$86,057 (34.8%)
Travel$23,728 (9.6%)
Research$19,508 (7.9%)
Food & Beverage$11,193 (4.5%)
Education$325.43 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $106,472 | 68 | 43.0% |
| Consulting Fee | $86,057 | 23 | 34.8% |
| Travel and Lodging | $23,728 | 82 | 9.6% |
| Unspecified | $19,508 | 23 | 7.9% |
| Food and Beverage | $11,193 | 226 | 4.5% |
| Education | $325.43 | 15 | 0.1% |
| Honoraria | $225.00 | 1 | 0.1% |
Payments by Type
General
$228,000
415 transactions
Research
$19,508
23 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | $117,410 | 141 | $0 (2022) |
| Novo Nordisk Inc | $113,845 | 165 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $12,496 | 66 | $0 (2019) |
| Becton, Dickinson and Company | $1,435 | 5 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $964.53 | 7 | $0 (2020) |
| Dexcom, Inc. | $240.59 | 8 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $181.75 | 14 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $166.69 | 2 | $0 (2019) |
| Abbott Laboratories | $118.15 | 6 | $0 (2019) |
| Senseonics, Incorporated | $106.00 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $1,250 | 1 | SANOFI-AVENTIS U.S. LLC ($1,250) |
| 2021 | $1,656 | 6 | SANOFI-AVENTIS U.S. LLC ($1,656) |
| 2020 | $14,513 | 21 | Novo Nordisk Inc ($9,234) |
| 2019 | $56,192 | 126 | Novo Nordisk Inc ($38,712) |
| 2018 | $79,870 | 128 | SANOFI-AVENTIS U.S. LLC ($47,197) |
| 2017 | $94,028 | 156 | SANOFI-AVENTIS U.S. LLC ($47,145) |
All Payment Transactions
438 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/01/2022 | SANOFI-AVENTIS U.S. LLC | TOUJEO (Biological) | — | In-kind items and services | $1,250.00 | Research |
| Study: Real-world insulin treatment persistence and health resource utilization in T2DM initiating or switching to Gla-300 • Category: Endocrine & Metabolic Diseases | ||||||
| 12/10/2021 | SANOFI-AVENTIS U.S. LLC | — | Food and Beverage | In-kind items and services | $77.15 | General |
| 09/27/2021 | SANOFI-AVENTIS U.S. LLC | TOUJEO (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: Real-world insulin treatment persistence and health resource utilization in T2DM initiating or switching to Gla-300 • Category: Endocrine & Metabolic Diseases | ||||||
| 09/27/2021 | SANOFI-AVENTIS U.S. LLC | TOUJEO (Biological) | — | In-kind items and services | $250.00 | Research |
| Study: Real-world insulin treatment persistence and health resource utilization in T2DM initiating or switching to Gla-300 • Category: Endocrine & Metabolic Diseases | ||||||
| 08/06/2021 | SANOFI-AVENTIS U.S. LLC | SOLIQUA 100/33 (Biological) | Food and Beverage | In-kind items and services | $78.48 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 06/25/2021 | SANOFI-AVENTIS U.S. LLC | TOUJEO (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: Real-world insulin treatment persistence and health resource utilization in T2DM initiating or switching to Gla-300 • Category: Endocrine & Metabolic Diseases | ||||||
| 06/25/2021 | SANOFI-AVENTIS U.S. LLC | TOUJEO (Biological) | — | In-kind items and services | $250.00 | Research |
| Study: Real-world insulin treatment persistence and health resource utilization in T2DM initiating or switching to Gla-300 • Category: Endocrine & Metabolic Diseases | ||||||
| 11/10/2020 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 11/10/2020 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 11/10/2020 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 11/10/2020 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 10/22/2020 | Novo Nordisk Inc | RYBELSUS (Drug) | Travel and Lodging | In-kind items and services | $45.08 | General |
| Category: Diabetes | ||||||
| 10/21/2020 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Education | In-kind items and services | $9.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/15/2020 | Novo Nordisk Inc | RYBELSUS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,092.50 | General |
| Category: Diabetes | ||||||
| 10/14/2020 | Novo Nordisk Inc | RYBELSUS (Drug) | Food and Beverage | In-kind items and services | $103.52 | General |
| Category: Diabetes | ||||||
| 10/12/2020 | Novo Nordisk Inc | RYBELSUS (Drug) | Travel and Lodging | In-kind items and services | $79.35 | General |
| Category: Diabetes | ||||||
| 10/09/2020 | Novo Nordisk Inc | RYBELSUS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,362.50 | General |
| Category: Diabetes | ||||||
| 10/08/2020 | Novo Nordisk Inc | RYBELSUS (Drug) | Food and Beverage | In-kind items and services | $88.62 | General |
| Category: Diabetes | ||||||
| 09/14/2020 | Novo Nordisk Inc | RYBELSUS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $229.50 | General |
| Category: Diabetes | ||||||
| 08/12/2020 | SANOFI-AVENTIS U.S. LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,347.50 | General |
| 08/07/2020 | SANOFI-AVENTIS U.S. LLC | SOLIQUA 100/33 (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $468.00 | General |
| Category: Endocrinology | ||||||
| 08/01/2020 | SANOFI-AVENTIS U.S. LLC | TOUJEO (Biological) | Consulting Fee | Cash or cash equivalent | $1,926.00 | General |
| Category: Endocrinology | ||||||
| 06/30/2020 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Consulting Fee | Cash or cash equivalent | $592.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/29/2020 | Novo Nordisk Inc | RYBELSUS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,350.00 | General |
| Category: Diabetes | ||||||
| 04/06/2020 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,295.00 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy (EDITION II) | SANOFI-AVENTIS U.S. LLC | $4,149 | 5 |
| Real-world insulin treatment persistence and health resource utilization in T2DM initiating or switching to Gla-300 | SANOFI-AVENTIS U.S. LLC | $2,750 | 5 |
| COACH 12 month ms; Impact of a Structured Patient Support Program on Adherence and Persistence at 12 months | SANOFI-AVENTIS U.S. LLC | $1,833 | 2 |
| Toujeo COACH | SANOFI-AVENTIS U.S. LLC | $1,752 | 1 |
| COACH Program | SANOFI-AVENTIS U.S. LLC | $1,460 | 1 |
| COACH 12 month manuscript: Impact of a Structured Patient Support Program on Adherence and Persistence at 12 months | SANOFI-AVENTIS U.S. LLC | $1,340 | 1 |
| 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naive Patients With Type 2 Diabetes | SANOFI-AVENTIS U.S. LLC | $1,252 | 1 |
| 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Both in Combination With Oral Antihyperglycemic | SANOFI-AVENTIS U.S. LLC | $1,206 | 1 |
| COACH 12 month ADA ps; Impact of a structured patient-support program on adherence and persistence with basal insulin therapy at 12 months | SANOFI-AVENTIS U.S. LLC | $992.64 | 1 |
| COACH 12 month ADA 2018 poster: Impact of a structured patient-support program on adherence and persistence with basal insulin therapy at 12 months | SANOFI-AVENTIS U.S. LLC | $812.16 | 1 |
| ToujeoCOACH12months_ADA2018 abstract: Impact of a structured patient-support program on adherence and persistence with basal insulin therapy at 12 months | SANOFI-AVENTIS U.S. LLC | $645.72 | 1 |
| Toujeo COACH Support Program | SANOFI-AVENTIS U.S. LLC | $538.10 | 1 |
| Evaluating Toujeo COACH Program- Retrospective Observational Claims | SANOFI-AVENTIS U.S. LLC | $411.40 | 1 |
| COACH 12-month | SANOFI-AVENTIS U.S. LLC | $366.30 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 3 | 145 | 149 | $12,306 | $5,335 |
| 2021 | 4 | 518 | 837 | $67,813 | $42,887 |
| 2020 | 4 | 469 | 749 | $47,593 | $31,688 |
Total Patients
1,132
Total Services
1,735
Medicare Billing
$79,910
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 75 | 79 | $7,837 | $3,559 | 45.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 55 | 55 | $3,719 | $1,458 | 39.2% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 15 | 15 | $750.92 | $317.33 | 42.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 249 | 407 | $40,713 | $26,477 | 65.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 213 | 341 | $23,092 | $14,484 | 62.7% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 40 | 72 | $3,867 | $1,848 | 47.8% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Office | 2021 | 16 | 17 | $140.13 | $77.63 | 55.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 222 | 359 | $28,201 | $19,052 | 67.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 217 | 355 | $18,070 | $11,956 | 66.2% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2020 | 18 | 22 | $1,212 | $619.60 | 51.1% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Office | 2020 | 12 | 13 | $110.50 | $60.56 | 54.8% |
About Dr. Timothy Reid, MD
Dr. Timothy Reid, MD is a Family Medicine healthcare provider based in Janesville, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/17/2007. The National Provider Identifier (NPI) number assigned to this provider is 1023160520.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Timothy Reid, MD has received a total of $247,508 in payments from pharmaceutical and medical device companies, with $1,250 received in 2022. These payments were reported across 438 transactions from 20 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($106,472).
As a Medicare-enrolled provider, Reid has provided services to 1,132 Medicare beneficiaries, totaling 1,735 services with total Medicare billing of $79,910. Data is available for 3 years (2020–2022), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Janesville, WI
- Active Since 01/17/2007
- Last Updated 11/16/2009
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1023160520
Products in Payments
- TOUJEO (Drug) $85,207
- Victoza (Drug) $44,315
- Tresiba (Drug) $30,479
- SOLIQUA (Drug) $17,424
- INVOKANA (Drug) $12,493
- Ozempic (Drug) $9,979
- RYBELSUS (Drug) $6,351
- Xultophy 100/3.6 (Drug) $6,065
- TOUJEO (Biological) $5,612
- SOLIQUA 100/33 (Drug) $4,615
- NO PRODUCT DISCUSSED (Drug) $2,281
- FARXIGA (Drug) $719.53
- SOLIQUA 100/33 (Biological) $546.48
- DIABETES - DISEASE (Drug) $289.58
- DEXCOM CGM (Device) $240.59
- Xultophy (Drug) $210.00
- JANUVIA (Drug) $129.30
- ONGLYZA (Drug) $125.00
- Eversense (Device) $106.00
- JARDIANCE (Drug) $98.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Janesville
Dr. Daniel Kulas, Md, MD
Family Medicine — Payments: $1,360
Family Medicine $1,360
Divya Sharma, Md, MD
Family Medicine — Payments: $1,247
Family Medicine $1,247
Dr. Jason Welch, Md, MD
Family Medicine — Payments: $1,125
Family Medicine $1,125
Jane Anderson, Md, MD
Family Medicine — Payments: $965.42
Family Medicine $965.42
Dr. Ronald Bowers, Md, MD
Family Medicine — Payments: $675.21
Family Medicine $675.21
Janet Barkhou, Md, MD
Family Medicine — Payments: $618.88
Family Medicine $618.88